JP2025506001A - ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 - Google Patents

２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 Download PDF

Info

Publication number
JP2025506001A
JP2025506001A JP2024546261A JP2024546261A JP2025506001A JP 2025506001 A JP2025506001 A JP 2025506001A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2024546261 A JP2024546261 A JP 2024546261A JP 2025506001 A JP2025506001 A JP 2025506001A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
acid
mbq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506001A5 (https=
Inventor
カスタルディ，エレナ
ザヒ，イリエス
カヴァイアー，ロベルト フォルメント
マイネロ，ヴァレンティナ
エフ マリアニ，マウリツィオ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2025506001A publication Critical patent/JP2025506001A/ja
Publication of JP2025506001A5 publication Critical patent/JP2025506001A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024546261A 2022-02-09 2023-02-09 ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 Pending JP2025506001A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308211P 2022-02-09 2022-02-09
US63/308,211 2022-02-09
PCT/IB2023/051159 WO2023152671A1 (en) 2022-02-09 2023-02-09 Pharmaceutical compositions comprising a 225-actinium-labelled complex and a bismuth sequestering agent

Publications (2)

Publication Number Publication Date
JP2025506001A true JP2025506001A (ja) 2025-03-05
JP2025506001A5 JP2025506001A5 (https=) 2026-02-06

Family

ID=85328574

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546261A Pending JP2025506001A (ja) 2022-02-09 2023-02-09 ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物

Country Status (5)

Country Link
US (1) US20250161502A1 (https=)
EP (1) EP4475900A1 (https=)
JP (1) JP2025506001A (https=)
CN (1) CN118647415A (https=)
WO (1) WO2023152671A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
WO2025218879A1 (en) * 2024-04-15 2025-10-23 Itm Technologies Munich Se Stable formulations comprising 225-actinium labeled complexes and methods for preparing the same
WO2025255396A1 (en) * 2024-06-05 2025-12-11 Ariceum Therapeutics Gmbh Radiopharmaceutical composition and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004273775C1 (en) * 2003-03-25 2010-03-04 Sloan-Kettering Institute For Cancer Research Methods for protection from toxicity of alpha emitting elements during radioimmunotherapy
RS65188B1 (sr) 2016-03-22 2024-03-29 Univ Johns Hopkins Sredstva sa visokim afinitetom za ciljano dejstvo na membranski antigen specifičan za prostatu za endoradioterapiju kancera prostate
CN111032632B (zh) * 2017-05-30 2024-04-12 约翰霍普金斯大学 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
JP7801207B2 (ja) 2019-07-08 2026-01-16 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
FI3997103T3 (fi) 2019-07-08 2025-02-03 3B Pharmaceuticals Gmbh Fibroblastien aktivaatioproteiinin ligandia käsittäviä yhdisteitä ja niiden käyttö
EP4178982A1 (en) * 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
IL303925A (en) 2021-01-07 2023-08-01 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
EP4050018A1 (en) 2021-01-07 2022-08-31 3B Pharmaceuticals GmbH Compounds comprising a fibroblast activation protein ligand and use thereof
EP4122499A1 (en) 2021-07-23 2023-01-25 3B Pharmaceuticals GmbH Fibroblast activation protein inhibitors and use thereof

Also Published As

Publication number Publication date
CN118647415A (zh) 2024-09-13
WO2023152671A1 (en) 2023-08-17
EP4475900A1 (en) 2024-12-18
US20250161502A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
Li et al. Functionally versatile and highly stable chelator for 111In and 177Lu: Proof-of-principle prostate-specific membrane antigen targeting
JP2025506001A (ja) ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物
AU2014396468B2 (en) Modified cyclopentapeptides and uses thereof
CN108290924B (zh) 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物
JP2020528461A (ja) デュアルモードの放射性トレーサーおよび療法剤
JP7673056B2 (ja) Ｇｒｐｒアンタゴニストを放射標識するための方法及びそれらのキット
JP7762648B2 (ja) 安定した濃縮放射性医薬組成物
SA96160495B1 (ar) استخدام ببتيدات سوماتوستاتين somatostatin peptides معقدة عديدة للتصوير الحيوي للأورام وانتشار الورم الموطب لمستقبل السوماتوستاتين somatostatin receptor
JP7646637B2 (ja) 画像化及び治療用組成物
KR20250073273A (ko) 고순도 구리 방사성 의약 조성물 및 이의 진단 및 치료 용도
Läppchen et al. In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector
US7122622B2 (en) Peptide compounds having improved binding affinity to somatostatin receptors
JP6410339B2 (ja) 放射性核種標識オクトレオチド誘導体
US20250313579A1 (en) Ligand compounds comprising a chelating group as a bridging group
US20240254085A1 (en) Chelators for radiometals and methods of making and using same
JP2023506297A (ja) 癌のイメージングおよび治療のための修飾されたｇｒｐｒアンタゴニストペプチド
CN113195005A (zh) 包含放射性标记的grpr拮抗剂和表面活性剂的药物组合物
RU2839656C1 (ru) Стабильная концентрированная радиофармацевтическая композиция
EP4631959A2 (en) Novel minigastrin-derived cholecystokinin 2 receptor binding molecules for imaging and targeted radiotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260129